{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T05:59:06Z","timestamp":1792735146390,"version":"4.5.0"},"reference-count":127,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,2,1]],"date-time":"2021-02-01T00:00:00Z","timestamp":1612137600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100012644","name":"Friends of FSH Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012644","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009824","name":"FSH Society","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009824","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","cell.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Trends in Molecular Medicine"],"published-print":{"date-parts":[[2021,2]]},"DOI":"10.1016\/j.molmed.2020.09.008","type":"journal-article","created":{"date-parts":[[2020,10,19]],"date-time":"2020-10-19T08:18:40Z","timestamp":1603095520000},"page":"123-137","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":45,"title":["Therapeutic Approaches in Facioscapulohumeral Muscular Dystrophy"],"prefix":"10.1016","volume":"27","author":[{"given":"Justin","family":"Cohen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alec","family":"DeSimone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monkol","family":"Lek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Lek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.molmed.2020.09.008_bb0005","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1212\/WNL.0000000000000797","article-title":"Population-based incidence and prevalence of facioscapulohumeral dystrophy","volume":"83","author":"Deenen","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.molmed.2020.09.008_bb0010","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1002\/j.2040-4603.2017.tb00779.x","article-title":"Facioscapulohumeral muscular dystrophy","volume":"7","author":"DeSimone","year":"2017","journal-title":"Compr. Physiol."},{"key":"10.1016\/j.molmed.2020.09.008_bb0015","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s13311-018-00675-3","article-title":"Facioscapulohumeral muscular dystrophy: update on pathogenesis and future treatments","volume":"15","author":"Hamel","year":"2018","journal-title":"Neurotherapeutics"},{"key":"10.1016\/j.molmed.2020.09.008_bb0020","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1055\/s-0037-1604197","article-title":"A pediatric review of facioscapulohumeral muscular dystrophy","volume":"16","author":"Mah","year":"2018","journal-title":"J. Pediatr. Neurol."},{"key":"10.1016\/j.molmed.2020.09.008_bb0025","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.nmd.2003.07.001","article-title":"Asymptomatic carriers and gender differences in facioscapulohumeral muscular dystrophy (FSHD)","volume":"14","author":"Tonini","year":"2004","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.molmed.2020.09.008_bb0030","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/j.ejpn.2018.04.013","article-title":"A 22-year follow-up reveals a variable disease severity in early-onset facioscapulohumeral dystrophy","volume":"22","author":"Goselink","year":"2018","journal-title":"Eur. J. Paediatr. Neurol."},{"key":"10.1016\/j.molmed.2020.09.008_bb0035","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.nmd.2006.06.008","article-title":"Severe phenotype in infantile facioscapulohumeral muscular dystrophy","volume":"16","author":"Klinge","year":"2006","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.molmed.2020.09.008_bb0040","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/ng0992-26","article-title":"Chromosome 4q DNA rearrangements associated with facioscapulohumeral muscular dystrophy","volume":"2","author":"Wijmenga","year":"1992","journal-title":"Nat. Genet."},{"key":"10.1016\/j.molmed.2020.09.008_bb0045","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0378-1119(99)00267-X","article-title":"Nucleotide sequence of the partially deleted D4Z4 locus in a patient with FSHD identifies a putative gene within each 3.3 kb element","volume":"236","author":"Gabriels","year":"1999","journal-title":"Gene"},{"key":"10.1016\/j.molmed.2020.09.008_bb0050","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1093\/hmg\/3.8.1287","article-title":"Analysis of the tandem repeat locus D4Z4 associated with facioscapulohumeral muscular dystrophy","volume":"3","author":"Hewitt","year":"1994","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.molmed.2020.09.008_bb0055","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1111\/cge.13726","article-title":"Consequences of epigenetic derepression in facioscapulohumeral muscular dystrophy","volume":"97","author":"Greco","year":"2020","journal-title":"Clin. Genet."},{"key":"10.1016\/j.molmed.2020.09.008_bb0060","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1097\/WCO.0b013e328357f22d","article-title":"Facioscapulohumeral muscular dystrophy: consequences of chromatin relaxation","volume":"25","author":"van der Maarel","year":"2012","journal-title":"Curr. Opin. Neurol."},{"key":"10.1016\/j.molmed.2020.09.008_bb0065","doi-asserted-by":"crossref","first-page":"1650","DOI":"10.1126\/science.1189044","article-title":"A unifying genetic model for facioscapulohumeral muscular dystrophy","volume":"329","author":"Lemmers","year":"2010","journal-title":"Science"},{"key":"10.1016\/j.molmed.2020.09.008_bb0070","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1038\/ng.2454","article-title":"Digenic inheritance of an SMCHD1 mutation and an FSHD-permissive D4Z4 allele causes facioscapulohumeral muscular dystrophy type 2","volume":"44","author":"Lemmers","year":"2012","journal-title":"Nat. Genet."},{"key":"10.1016\/j.molmed.2020.09.008_bb0075","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1016\/j.ajhg.2016.03.013","article-title":"Mutations in DNMT3B modify epigenetic repression of the D4Z4 repeat and the penetrance of facioscapulohumeral dystrophy","volume":"98","author":"van den Boogaard","year":"2016","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.molmed.2020.09.008_bb0080","doi-asserted-by":"crossref","first-page":"e2441","DOI":"10.1212\/WNL.0000000000009617","article-title":"Homozygous nonsense variant in LRIF1 associated with facioscapulohumeral muscular dystrophy","volume":"94","author":"Hamanaka","year":"2020","journal-title":"Neurology"},{"key":"10.1016\/j.molmed.2020.09.008_bb0085","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1002\/ana.20106","article-title":"Somatic mosaicism in FSHD often goes undetected","volume":"55","author":"Lemmers","year":"2004","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.molmed.2020.09.008_bb0090","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1146\/annurev-genom-083118-014933","article-title":"The genetics and epigenetics of facioscapulohumeral muscular dystrophy","volume":"20","author":"Himeda","year":"2019","journal-title":"Annu. Rev. Genomics Hum. Genet."},{"key":"10.1016\/j.molmed.2020.09.008_bb0095","article-title":"Functional domains of the FSHD-associated DUX4 protein","volume":"7","author":"Mitsuhashi","year":"2018","journal-title":"Biol. Open"},{"key":"10.1016\/j.molmed.2020.09.008_bb0100","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1038\/ng.3858","article-title":"DUX-family transcription factors regulate zygotic genome activation in placental mammals","volume":"49","author":"De Iaco","year":"2017","journal-title":"Nat. Genet."},{"key":"10.1016\/j.molmed.2020.09.008_bb0105","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1038\/ng.3844","article-title":"Conserved roles of mouse DUX and human DUX4 in activating cleavage-stage genes and MERVL\/HERVL retrotransposons","volume":"49","author":"Hendrickson","year":"2017","journal-title":"Nat. Genet."},{"key":"10.1016\/j.molmed.2020.09.008_bb0110","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1038\/ng.3846","article-title":"Conservation and innovation in the DUX4-family gene network","volume":"49","author":"Whiddon","year":"2017","journal-title":"Nat. Genet."},{"key":"10.1016\/j.molmed.2020.09.008_bb0115","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.devcel.2011.11.013","article-title":"DUX4 activates germline genes, retroelements, and immune mediators: implications for facioscapulohumeral dystrophy","volume":"22","author":"Geng","year":"2012","journal-title":"Dev. Cell"},{"key":"10.1016\/j.molmed.2020.09.008_bb0120","doi-asserted-by":"crossref","first-page":"4024","DOI":"10.1093\/hmg\/ddy293","article-title":"A patient-derived iPSC model revealed oxidative stress increases facioscapulohumeral muscular dystrophy-causative DUX4","volume":"27","author":"Sasaki-Honda","year":"2018","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.molmed.2020.09.008_bb0125","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/j.freeradbiomed.2012.06.041","article-title":"Functional muscle impairment in facioscapulohumeral muscular dystrophy is correlated with oxidative stress and mitochondrial dysfunction","volume":"53","author":"Turki","year":"2012","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.molmed.2020.09.008_bb0130","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1007\/s00415-019-09242-y","article-title":"Relationship between muscle inflammation and fat replacement assessed by MRI in facioscapulohumeral muscular dystrophy","volume":"266","author":"Dahlqvist","year":"2019","journal-title":"J. Neurol."},{"key":"10.1016\/j.molmed.2020.09.008_bb0135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1006658","article-title":"DUX4-induced dsRNA and MYC mRNA stabilization activate apoptotic pathways in human cell models of facioscapulohumeral dystrophy","volume":"13","author":"Shadle","year":"2017","journal-title":"PLoS Genet."},{"key":"10.1016\/j.molmed.2020.09.008_bb0140","doi-asserted-by":"crossref","first-page":"5901","DOI":"10.1093\/hmg\/ddv315","article-title":"Endogenous DUX4 expression in FSHD myotubes is sufficient to cause cell death and disrupts RNA splicing and cell migration pathways","volume":"24","author":"Rickard","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.molmed.2020.09.008_bb0145","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1002\/ana.22275","article-title":"DUX4, a candidate gene for facioscapulohumeral muscular dystrophy, causes p53-dependent myopathy in vivo","volume":"69","author":"Wallace","year":"2011","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.molmed.2020.09.008_bb0150","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.04996","article-title":"A feedback loop between nonsense-mediated decay and the retrogene DUX4 in facioscapulohumeral muscular dystrophy","volume":"4","author":"Feng","year":"2015","journal-title":"eLife"},{"key":"10.1016\/j.molmed.2020.09.008_bb0155","doi-asserted-by":"crossref","first-page":"3816","DOI":"10.1242\/jcs.180372","article-title":"DUX4 induces a transcriptome more characteristic of a less-differentiated cell state and inhibits myogenesis","volume":"129","author":"Knopp","year":"2016","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.molmed.2020.09.008_bb0160","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1185\/03007990903155915","article-title":"Appropriate use of inhaled corticosteroid and long-acting \u03b22-adrenergic agonist combination therapy among asthma patients in a US commercially insured population","volume":"25","author":"Ye","year":"2009","journal-title":"Curr. Med. Res. Opin."},{"key":"10.1016\/j.molmed.2020.09.008_bb0165","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1113\/jphysiol.2003.056770","article-title":"\u03b22-Agonist administration reverses muscle wasting and improves muscle function in aged rats","volume":"555","author":"Ryall","year":"2004","journal-title":"J. Physiol."},{"key":"10.1016\/j.molmed.2020.09.008_bb0170","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1152\/physrev.00028.2007","article-title":"Role of beta-adrenoceptor signaling in skeletal muscle: implications for muscle wasting and disease","volume":"88","author":"Lynch","year":"2008","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.molmed.2020.09.008_bb0175","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1212\/WNL.50.5.1402","article-title":"Pilot trial of albuterol in facioscapulohumeral muscular dystrophy. FSH-DY Group","volume":"50","author":"Kissel","year":"1998","journal-title":"Neurology"},{"key":"10.1016\/j.molmed.2020.09.008_bb0180","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1212\/WNL.57.8.1434","article-title":"Randomized, double-blind, placebo-controlled trial of albuterol in facioscapulohumeral dystrophy","volume":"57","author":"Kissel","year":"2001","journal-title":"Neurology"},{"key":"10.1016\/j.molmed.2020.09.008_bb0185","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1249\/00005768-199511000-00002","article-title":"The effects of albuterol and isokinetic exercise on the quadriceps muscle group","volume":"27","author":"Caruso","year":"1995","journal-title":"Med. Sci. Sports Exerc."},{"key":"10.1016\/j.molmed.2020.09.008_bb0190","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1212\/01.WNL.0000134660.30793.1F","article-title":"Strength training and albuterol in facioscapulohumeral muscular dystrophy","volume":"63","author":"van der Kooi","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.molmed.2020.09.008_bb0195","first-page":"93","article-title":"Down-regulation of rat beta-adrenoceptors by clenbuterol or desipramine does not require chronic treatment: [3H]CGP-12177 binding reveals rapid (24 hour) modulation","volume":"41","author":"Newman-Tancredi","year":"1996","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.molmed.2020.09.008_bb0200","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.apmr.2008.12.027","article-title":"Periodic salbutamol in facioscapulohumeral muscular dystrophy: a randomized controlled trial","volume":"90","author":"Payan","year":"2009","journal-title":"Arch. Phys. Med. Rehabil."},{"key":"10.1016\/j.molmed.2020.09.008_bb0205","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s13395-017-0134-x","article-title":"BET bromodomain inhibitors and agonists of the beta-2 adrenergic receptor identified in screens for compounds that inhibit DUX4 expression in FSHD muscle cells","volume":"7","author":"Campbell","year":"2017","journal-title":"Skelet. Muscle"},{"key":"10.1016\/j.molmed.2020.09.008_bb0210","first-page":"698","article-title":"Therapeutic trial of beta 2-adrenergic agonist clenbuterol in muscular dystrophies [in Japanese]","volume":"41","author":"Oya","year":"2001","journal-title":"Rinsho Shinkeigaku"},{"key":"10.1016\/j.molmed.2020.09.008_bb0215","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s12970-017-0173-z","article-title":"International Society of Sports Nutrition position stand: safety and efficacy of creatine supplementation in exercise, sport, and medicine","volume":"14","author":"Kreider","year":"2017","journal-title":"J. Int. Soc. Sports Nutr."},{"key":"10.1016\/j.molmed.2020.09.008_bb0220","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/0022-510X(93)90326-T","article-title":"Cellular energetics of dystrophic muscle","volume":"116","author":"Kemp","year":"1993","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.molmed.2020.09.008_bb0225","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.mri.2010.03.008","article-title":"Effect of creatine monohydrate in improving cellular energetics and muscle strength in ambulatory Duchenne muscular dystrophy patients: a randomized, placebo-controlled 31P MRS study","volume":"28","author":"Banerjee","year":"2010","journal-title":"Magn. Reson. Imaging"},{"key":"10.1016\/j.molmed.2020.09.008_bb0230","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD004760.pub3","article-title":"Creatine for treating muscle disorders","volume":"2","author":"Kley","year":"2011","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.molmed.2020.09.008_bb0235","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1212\/WNL.54.9.1848","article-title":"Creatine monohydrate in muscular dystrophies: a double-blind, placebo-controlled clinical study","volume":"54","author":"Walter","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.molmed.2020.09.008_bb0240","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1212\/WNL.52.1.151","article-title":"Impact of neurologic signs and symptoms on functional status in peripheral neuropathies","volume":"52","author":"Molenaar","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/j.molmed.2020.09.008_bb0245","first-page":"661","article-title":"A clinical trial of creatine monohydrate in muscular dystrophy patients [in Japanese]","volume":"44","author":"Matsumura","year":"2004","journal-title":"Rinsho Shinkeigaku"},{"key":"10.1016\/j.molmed.2020.09.008_bb0250","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1186\/1471-2474-15-155","article-title":"An integrated approach in a case of facioscapulohumeral dystrophy","volume":"15","author":"Pasotti","year":"2014","journal-title":"BMC Musculoskelet. Disord."},{"key":"10.1016\/j.molmed.2020.09.008_bb0255","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1146\/annurev.cellbio.20.012103.135836","article-title":"Regulation of muscle mass by myostatin","volume":"20","author":"Lee","year":"2004","journal-title":"Annu. Rev. Cell Dev. Biol."},{"key":"10.1016\/j.molmed.2020.09.008_bb0260","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/SPC.0000000000000013","article-title":"Myostatin inhibitors as therapies for muscle wasting associated with cancer and other disorders","volume":"7","author":"Smith","year":"2013","journal-title":"Curr. Opin. Support. Palliat. Care"},{"key":"10.1016\/j.molmed.2020.09.008_bb0265","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/ana.21338","article-title":"A phase I\/II trial of MYO-029 in adult subjects with muscular dystrophy","volume":"63","author":"Wagner","year":"2008","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.molmed.2020.09.008_bb0270","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.1210\/en.2006-0089","article-title":"Biological activity of follistatin isoforms and follistatin-like-3 is dependent on differential cell surface binding and specificity for activin, myostatin, and bone morphogenetic proteins","volume":"147","author":"Sidis","year":"2006","journal-title":"Endocrinology"},{"key":"10.1016\/j.molmed.2020.09.008_bb0275","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1002\/mus.26113","article-title":"Locally acting ACE-083 increases muscle volume in healthy volunteers","volume":"57","author":"Glasser","year":"2018","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.molmed.2020.09.008_bb0280","doi-asserted-by":"crossref","first-page":"11392","DOI":"10.1038\/s41598-019-47818-w","article-title":"Follistatin-based ligand trap ACE-083 induces localized hypertrophy of skeletal muscle with functional improvement in models of neuromuscular disease","volume":"9","author":"Pearsall","year":"2019","journal-title":"Sci. Rep."},{"key":"10.1016\/j.molmed.2020.09.008_bb0285","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.123538","article-title":"AAV-mediated follistatin gene therapy improves functional outcomes in the TIC-DUX4 mouse model of FSHD","volume":"3","author":"Giesige","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.molmed.2020.09.008_bb0290","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1016\/S2213-8587(15)00298-3","article-title":"Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial","volume":"3","author":"Becker","year":"2015","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.molmed.2020.09.008_bb0295","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1002\/mus.880181312","article-title":"Inflammatory response in facioscapulohumeral muscular dystrophy (FSHD): immunocytochemical and genetic analyses","volume":"2","author":"Arahata","year":"1995","journal-title":"Muscle Nerve Suppl."},{"key":"10.1016\/j.molmed.2020.09.008_bb0300","doi-asserted-by":"crossref","first-page":"25","DOI":"10.2344\/0003-3006-60.1.25","article-title":"Basic and clinical pharmacology of glucocorticosteroids","volume":"60","author":"Becker","year":"2013","journal-title":"Anesth. Prog."},{"key":"10.1016\/j.molmed.2020.09.008_bb0305","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/mus.20812","article-title":"The role of corticosteroids in muscular dystrophy: a critical appraisal","volume":"36","author":"Angelini","year":"2007","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.molmed.2020.09.008_bb0310","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD003725.pub4","article-title":"Corticosteroids for the treatment of Duchenne muscular dystrophy","author":"Matthews","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.molmed.2020.09.008_bb0315","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1212\/WNL.22.4.335","article-title":"Inflammatory myopathy with facioscapulohumeral distribution","volume":"22","author":"Munsat","year":"1972","journal-title":"Neurology"},{"key":"10.1016\/j.molmed.2020.09.008_bb0320","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/0022-510X(73)90061-0","article-title":"\u2018Polymyositis\u2019 with involvement of facial and distal musculature: one form of the fascioscapulohumeral syndrome?","volume":"19","author":"Bates","year":"1973","journal-title":"J. Neurol. Sci."},{"key":"10.1016\/j.molmed.2020.09.008_bb0325","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1002\/ana.410120415","article-title":"Inflammatory facioscapulohumeral muscular dystrophy and Coats syndrome","volume":"12","author":"Wulff","year":"1982","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.molmed.2020.09.008_bb0330","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1212\/WNL.48.1.46","article-title":"A pilot trial of prednisone in facioscapulohumeral muscular dystrophy. FSH-DY Group","volume":"48","author":"Tawil","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.molmed.2020.09.008_bb0335","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1136\/jmedgenet-2011-100101","article-title":"Patients with a phenotype consistent with facioscapulohumeral muscular dystrophy display genetic and epigenetic heterogeneity","volume":"49","author":"Sacconi","year":"2012","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.molmed.2020.09.008_bb0340","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s13555-018-0221-x","article-title":"Nutraceuticals: a review","volume":"8","author":"Souyoul","year":"2018","journal-title":"Dermatol. Ther. (Heidelb)"},{"key":"10.1016\/j.molmed.2020.09.008_bb0345","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1016\/j.nmd.2006.08.005","article-title":"No effect of folic acid and methionine supplementation on D4Z4 methylation in patients with facioscapulohumeral muscular dystrophy","volume":"16","author":"van der Kooi","year":"2006","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.molmed.2020.09.008_bb0350","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.freeradbiomed.2014.09.014","article-title":"Effects of vitamin C, vitamin E, zinc gluconate, and selenomethionine supplementation on muscle function and oxidative stress biomarkers in patients with facioscapulohumeral dystrophy: a double-blind randomized controlled clinical trial","volume":"81","author":"Passerieux","year":"2015","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.molmed.2020.09.008_bb0355","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0146132","article-title":"Brugia malayi asparaginyl-tRNA synthetase stimulates endothelial cell proliferation, vasodilation and angiogenesis","volume":"11","author":"D","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.molmed.2020.09.008_bb0360","doi-asserted-by":"crossref","first-page":"S199","DOI":"10.1016\/j.nmd.2017.06.381","article-title":"Results of a phase 1b\/2 study of ATYR1940 in adolescents and young adults with early onset facioscapulohumeral muscular dystrophy (FSHD) (ATYR1940-C-003) [abstract]","volume":"27","author":"Walker","year":"2017","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.molmed.2020.09.008_bb0365","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJM199607043350101","article-title":"The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men","volume":"335","author":"Bhasin","year":"1996","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.molmed.2020.09.008_bb0370","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1002\/ana.410200506","article-title":"Effect of testosterone on muscle protein synthesis in myotonic dystrophy","volume":"20","author":"Griggs","year":"1986","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.molmed.2020.09.008_bb0375","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1055\/s-0035-1563696","article-title":"Testosterone treatment of pubertal delay in Duchenne muscular dystrophy","volume":"46","author":"Wood","year":"2015","journal-title":"Neuropediatrics"},{"key":"10.1016\/j.molmed.2020.09.008_bb0380","doi-asserted-by":"crossref","first-page":"3274","DOI":"10.1210\/jcem.87.7.8597","article-title":"The effect of long-term pharmacological antilipolysis on substrate metabolism in growth hormone (GH)-substituted GH-deficient adults","volume":"87","author":"Nielsen","year":"2002","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.molmed.2020.09.008_bb0385","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.nmd.2017.01.015","article-title":"Human growth hormone stabilizes walking and improves strength in a patient with dominantly inherited calpainopathy","volume":"27","author":"Prahm","year":"2017","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.molmed.2020.09.008_bb0390","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1124\/jpet.119.259663","article-title":"Clinically advanced p38 inhibitors suppress DUX4 expression in cellular and animal models of facioscapulohumeral muscular dystrophy","volume":"370","author":"Oliva","year":"2019","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.molmed.2020.09.008_bb0395","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1128\/MCB.01466-08","article-title":"Hematopoietic protein tyrosine phosphatase mediates \u03b22-adrenergic receptor-induced regulation of p38 mitogen-activated protein kinase in B lymphocytes","volume":"29","author":"McAlees","year":"2009","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.molmed.2020.09.008_bb0400","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0014-5793(98)01392-1","article-title":"The activation of p38 MAPK by the beta-adrenergic agonist isoproterenol in rat epididymal fat cells","volume":"439","author":"Moule","year":"1998","journal-title":"FEBS Lett."},{"key":"10.1016\/j.molmed.2020.09.008_bb0405","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1124\/jpet.119.264689","article-title":"P38alpha regulates expression of DUX4 in facioscapulohumeral muscular dystrophy","volume":"374","author":"Rojas","year":"2020","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.molmed.2020.09.008_bb0410","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1002\/mus.26088","article-title":"Facioscapulohumeral muscular dystrophy functional composite outcome measure","volume":"58","author":"Eichinger","year":"2018","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.molmed.2020.09.008_bb0415","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.molmed.2015.02.011","article-title":"Emerging preclinical animal models for FSHD","volume":"21","author":"Lek","year":"2015","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.molmed.2020.09.008_bb0420","first-page":"4419","article-title":"Model systems of DUX4 expression recapitulate the transcriptional profile of FSHD cells","volume":"25","author":"Jagannathan","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.molmed.2020.09.008_bb0425","doi-asserted-by":"crossref","first-page":"20140797","DOI":"10.1098\/rsif.2014.0797","article-title":"\u03b2-Catenin is central to DUX4-driven network rewiring in facioscapulohumeral muscular dystrophy","volume":"12","author":"Banerji","year":"2015","journal-title":"J. R. Soc. Interface"},{"key":"10.1016\/j.molmed.2020.09.008_bb0430","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aay0271","article-title":"Applying genome-wide CRISPR-Cas9 screens for therapeutic discovery in facioscapulohumeral muscular dystrophy","volume":"12","author":"Lek","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.molmed.2020.09.008_bb0435","first-page":"67","article-title":"Gene expression during normal and FSHD myogenesis","volume":"4","author":"Tsumagari","year":"2011","journal-title":"BMC Med. Genet."},{"key":"10.1016\/j.molmed.2020.09.008_bb0440","doi-asserted-by":"crossref","first-page":"4661","DOI":"10.1093\/hmg\/ddt314","article-title":"Wnt\/beta-catenin signaling suppresses DUX4 expression and prevents apoptosis of FSHD muscle cells","volume":"22","author":"Block","year":"2013","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.molmed.2020.09.008_bb0445","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0146893","article-title":"Homologous transcription factors DUX4 and DUX4c associate with cytoplasmic proteins during muscle differentiation","volume":"11","author":"Ansseau","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.molmed.2020.09.008_bb0450","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aaw7099","article-title":"Identification of the hyaluronic acid pathway as a therapeutic target for facioscapulohumeral muscular dystrophy","volume":"5","author":"DeSimone","year":"2019","journal-title":"Sci. Adv."},{"key":"10.1016\/j.molmed.2020.09.008_bb0455","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1093\/hmg\/ddz242","article-title":"DUX4-induced bidirectional HSATII satellite repeat transcripts form intranuclear double stranded RNA foci in human cell models of FSHD","volume":"28","author":"Shadle","year":"2019","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.molmed.2020.09.008_bb0460","doi-asserted-by":"crossref","first-page":"5161","DOI":"10.1093\/nar\/gkw141","article-title":"DUX4 recruits p300\/CBP through its C-terminus and induces global H3K27 acetylation changes","volume":"44","author":"Choi","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.molmed.2020.09.008_bb0465","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.aaw7781","article-title":"A novel P300 inhibitor reverses DUX4-mediated global histone H3 hyperacetylation, target gene expression, and cell death","volume":"5","author":"Bosnakovski","year":"2019","journal-title":"Sci. Adv."},{"key":"10.1016\/j.molmed.2020.09.008_bb0470","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1038\/ncb1534","article-title":"Interaction between beta-catenin and HIF-1 promotes cellular adaptation to hypoxia","volume":"9","author":"Kaidi","year":"2007","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.molmed.2020.09.008_bb0475","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.apsb.2015.05.007","article-title":"HIF-1alpha pathway: role, regulation and intervention for cancer therapy","volume":"5","author":"Masoud","year":"2015","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.molmed.2020.09.008_bb0480","doi-asserted-by":"crossref","first-page":"10220","DOI":"10.1128\/MCB.25.23.10220-10234.2005","article-title":"Dual regulation of c-Myc by p300 via acetylation-dependent control of Myc protein turnover and coactivation of Myc-induced transcription","volume":"25","author":"Faiola","year":"2005","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.molmed.2020.09.008_bb0485","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1016\/j.bbagen.2014.02.001","article-title":"Hyaluronan: biosynthesis and signaling","volume":"1840","author":"Vigetti","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.molmed.2020.09.008_bb0490","doi-asserted-by":"crossref","first-page":"7607","DOI":"10.1158\/1078-0432.CCR-05-0981","article-title":"Signal pathway of hypoxia-inducible factor-1alpha phosphorylation and its interaction with von Hippel-Lindau tumor suppressor protein during ischemia in MiaPaCa-2 pancreatic cancer cells","volume":"11","author":"Kwon","year":"2005","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.molmed.2020.09.008_bb0495","doi-asserted-by":"crossref","first-page":"2269","DOI":"10.1038\/jid.2010.93","article-title":"A p38(MAPK)\/HIF-1 pathway initiated by UVB irradiation is required to induce Noxa and apoptosis of human keratinocytes","volume":"130","author":"Nys","year":"2010","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.molmed.2020.09.008_bb0500","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1038\/mt.2016.111","article-title":"Morpholino-mediated knockdown of DUX4 toward facioscapulohumeral muscular dystrophy therapeutics","volume":"24","author":"Chen","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.molmed.2020.09.008_bb0505","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1093\/hmg\/ddw015","article-title":"Antisense targeting of 3\u2032 end elements involved in DUX4 mRNA processing is an efficient therapeutic strategy for facioscapulohumeral dystrophy: a new gene-silencing approach","volume":"25","author":"Marsollier","year":"2016","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.molmed.2020.09.008_bb0510","doi-asserted-by":"crossref","DOI":"10.3390\/genes8030093","article-title":"Antisense oligonucleotides used to target the DUX4 mRNA as therapeutic approaches in facioscapulohumeral muscular dystrophy (FSHD)","volume":"8","author":"Ansseau","year":"2017","journal-title":"Genes (Basel)"},{"key":"10.1016\/j.molmed.2020.09.008_bb0515","doi-asserted-by":"crossref","first-page":"16509","DOI":"10.1073\/pnas.1909649117","article-title":"Inhibition of DUX4 expression with antisense LNA gapmers as a therapy for facioscapulohumeral muscular dystrophy","volume":"117","author":"Lim","year":"2020","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.molmed.2020.09.008_bb0520","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1038\/mt.2012.68","article-title":"RNA interference inhibits DUX4-induced muscle toxicity in vivo: implications for a targeted FSHD therapy","volume":"20","author":"Wallace","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.molmed.2020.09.008_bb0525","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.omtm.2017.12.005","article-title":"Pre-clinical safety and off-target studies to support translation of AAV-mediated RNAi therapy for FSHD","volume":"8","author":"Wallace","year":"2018","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.molmed.2020.09.008_bb0530","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1136\/jmedgenet-2019-106402","article-title":"Intronic SMCHD1 variants in FSHD: testing the potential for CRISPR-Cas9 genome editing","volume":"56","author":"Goossens","year":"2019","journal-title":"J. Med. Genet."},{"key":"10.1016\/j.molmed.2020.09.008_bb0535","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.tips.2016.02.001","article-title":"Scalpel or straitjacket: CRISPR\/Cas9 approaches for muscular dystrophies","volume":"37","author":"Himeda","year":"2016","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.molmed.2020.09.008_bb0540","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/mt.2015.200","article-title":"CRISPR\/dCas9-mediated transcriptional inhibition ameliorates the epigenetic dysregulation at D4Z4 and represses DUX4-fl in FSH muscular dystrophy","volume":"24","author":"Himeda","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.molmed.2020.09.008_bb0545","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1002\/ana.24555","article-title":"Longitudinal effect of eteplirsen versus historical control on ambulation in Duchenne muscular dystrophy","volume":"79","author":"Mendell","year":"2016","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.molmed.2020.09.008_bb0550","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1016\/S1474-4422(14)70195-4","article-title":"Safety and efficacy of drisapersen for the treatment of Duchenne muscular dystrophy (DEMAND II): an exploratory, randomised, placebo-controlled phase 2 study","volume":"13","author":"Voit","year":"2014","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.molmed.2020.09.008_bb0555","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1212\/WNL.48.1.38","article-title":"A prospective, quantitative study of the natural history of facioscapulohumeral muscular dystrophy (FSHD): implications for therapeutic trials","volume":"48","author":"FSH-DY Group","year":"1997","journal-title":"Neurology"},{"key":"10.1016\/j.molmed.2020.09.008_bb0560","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1002\/mus.23529","article-title":"Patient-identified disease burden in facioscapulohumeral muscular dystrophy","volume":"46","author":"Johnson","year":"2012","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.molmed.2020.09.008_bb0565","article-title":"Towards wearable comprehensive capture and analysis of skeletal muscle activity during human locomotion","volume":"19","author":"Ma","year":"2019","journal-title":"Sensors (Basel)"},{"key":"10.1016\/j.molmed.2020.09.008_bb0570","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.nmd.2016.04.012","article-title":"A cross sectional study of two independent cohorts identifies serum biomarkers for facioscapulohumeral muscular dystrophy (FSHD)","volume":"26","author":"Petek","year":"2016","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/j.molmed.2020.09.008_bb0575","doi-asserted-by":"crossref","first-page":"181","DOI":"10.3233\/JND-140034","article-title":"Multiplex screen of serum biomarkers in facioscapulohumeral muscular dystrophy","volume":"1","author":"Statland","year":"2014","journal-title":"J. Neuromuscul. Dis."},{"key":"10.1016\/j.molmed.2020.09.008_bb0580","doi-asserted-by":"crossref","first-page":"2224","DOI":"10.1093\/hmg\/ddz043","article-title":"PAX7 target gene repression is a superior FSHD biomarker than DUX4 target gene activation, associating with pathological severity and identifying FSHD at the single-cell level","volume":"28","author":"Banerji","year":"2019","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.molmed.2020.09.008_bb0585","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1093\/hmg\/ddy364","article-title":"MRI-informed muscle biopsies correlate MRI with pathology and DUX4 target gene expression in FSHD","volume":"28","author":"Wang","year":"2019","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.molmed.2020.09.008_bb0590","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1093\/hmg\/ddaa031","article-title":"Longitudinal measures of RNA expression and disease activity in FSHD muscle biopsies","volume":"29","author":"Wong","year":"2020","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.molmed.2020.09.008_bb0595","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1007\/s00415-018-9037-y","article-title":"Quantitative muscle MRI and ultrasound for facioscapulohumeral muscular dystrophy: complementary imaging biomarkers","volume":"265","author":"Mul","year":"2018","journal-title":"J. Neurol."},{"key":"10.1016\/j.molmed.2020.09.008_bb0600","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1186\/s12883-019-1452-x","article-title":"Clinical trial readiness to solve barriers to drug development in FSHD (ReSolve): protocol of a large, international, multi-center prospective study","volume":"19","author":"LoRusso","year":"2019","journal-title":"BMC Neurol."},{"key":"10.1016\/j.molmed.2020.09.008_bb0605","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/mus.26792","article-title":"Magnetic resonance imaging correlates with electrical impedance myography in facioscapulohumeral muscular dystrophy","volume":"61","author":"Hamel","year":"2020","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.molmed.2020.09.008_bb0610","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1002\/mus.26127","article-title":"Electrical impedance myography in facioscapulohumeral muscular dystrophy: a 1-year follow-up study","volume":"58","author":"Mul","year":"2018","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.molmed.2020.09.008_bb0615","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1002\/mus.25065","article-title":"Electrical impedance myography in facioscapulohumeral muscular dystrophy","volume":"54","author":"Statland","year":"2016","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.molmed.2020.09.008_bb0620","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1089\/hum.2009.182","article-title":"Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors","volume":"21","author":"Boutin","year":"2010","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.molmed.2020.09.008_bb0625","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/s41591-020-0911-7","article-title":"IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies","volume":"26","author":"Leborgne","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.molmed.2020.09.008_bb0630","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1016\/j.cell.2013.08.021","article-title":"Double nicking by RNA-guided CRISPR Cas9 for enhanced genome editing specificity","volume":"154","author":"Ran","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.molmed.2020.09.008_bb0635","doi-asserted-by":"crossref","first-page":"755","DOI":"10.3389\/fneur.2019.00755","article-title":"Preliminary evidences of safety and efficacy of flavonoids- and omega 3-based compound for muscular dystrophies treatment: a randomized double-blind placebo controlled pilot clinical trial","volume":"10","author":"Sitzia","year":"2019","journal-title":"Front. Neurol."}],"container-title":["Trends in Molecular Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491420302392?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471491420302392?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T07:21:37Z","timestamp":1761463297000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471491420302392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2]]},"references-count":127,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,2]]}},"alternative-id":["S1471491420302392"],"URL":"https:\/\/doi.org\/10.1016\/j.molmed.2020.09.008","relation":{},"ISSN":["1471-4914"],"issn-type":[{"value":"1471-4914","type":"print"}],"subject":[],"published":{"date-parts":[[2021,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapeutic Approaches in Facioscapulohumeral Muscular Dystrophy","name":"articletitle","label":"Article Title"},{"value":"Trends in Molecular Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.molmed.2020.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}